BPCA
IOVA icon

Bank Pictet & Cie (Asia)’s Iovance Biotherapeutics IOVA Stock Holding History

Bank Pictet & Cie (Asia)’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-11,227
Closed -$91.3K – 108
2023
Q4 		$91.3K Buy
+11,227
New +$58.7K 0.02% 97

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank Pictet & Cie (Asia)'s IOVA Position: Q1 2024 in Review

Bank Pictet & Cie (Asia) sold out of Iovance Biotherapeutics (IOVA) in Q1 2024, closing a stake of 11,227 shares — an estimated $91.3K sold.

Bank Pictet & Cie (Asia) first reported a position in IOVA in Q4 2023 and held it in 1 quarter. The position peaked at $91.3K in Q4 2023. 273 funds tracked by Wall St. Rank hold IOVA as of Q1 2024.

  • Bank Pictet & Cie (Asia) reported no remaining Iovance Biotherapeutics position as of Q1 2024 after selling out during the quarter.
  • Bank Pictet & Cie (Asia) sold 11,227 Iovance Biotherapeutics shares in Q1 2024, an estimated $91.3K.
  • Bank Pictet & Cie (Asia) first reported a position in Iovance Biotherapeutics in Q4 2023 and held it in 1 quarter.
  • Bank Pictet & Cie (Asia)'s Iovance Biotherapeutics position peaked at $91.3K in Q4 2023.
  • 273 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2024.

Based on Bank Pictet & Cie (Asia)'s 13F filing for Q1 2024, filed 7 May 2024.